M
Michelle Harrison
Researcher at Washington University in St. Louis
Publications - 2
Citations - 1542
Michelle Harrison is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Exome & Cancer. The author has an hindex of 2, co-authored 2 publications receiving 1411 citations.
Papers
More filters
Journal ArticleDOI
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis,Li Ding,Dong Shen,Jingqin Luo,Vera J. Suman,John W. Wallis,Brian A. Van Tine,Jeremy Hoog,Reece J. Goiffon,Theodore C. Goldstein,Sam Ng,Li Lin,Robert J. Crowder,Jacqueline E. Snider,Karla V. Ballman,Jason D. Weber,Ken Chen,Daniel C. Koboldt,Cyriac Kandoth,William Schierding,Joshua F. McMichael,Christopher A. Miller,Charles Lu,Chris Harris,Michael D. McLellan,Michael C. Wendl,Katherine DeSchryver,D. Craig Allred,Laura J. Esserman,Gary Unzeitig,Julie A. Margenthaler,Gildy Babiera,P. Kelly Marcom,J. M. Guenther,Marilyn Leitch,Kelly K. Hunt,John A. Olson,Yu Tao,Christopher G. Maher,Lucinda Fulton,Robert S. Fulton,Michelle Harrison,Ben Oberkfell,Feiyu Du,Ryan Demeter,Tammi L. Vickery,Adnan Elhammali,Helen Piwnica-Worms,Helen Piwnica-Worms,Sandra McDonald,Mark A. Watson,David J. Dooling,David M. Ota,Li-Wei Chang,Ron Bose,Timothy J. Ley,David Piwnica-Worms,Joshua M. Stuart,Richard K. Wilson,Elaine R. Mardis +59 more
TL;DR: To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy are studied by massively parallel sequencing and analysis.
Journal ArticleDOI
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li,Dong Shen,Jieya Shao,Robert J. Crowder,Wenbin Liu,Aleix Prat,Xiaping He,Shuying Liu,Jeremy Hoog,Charles Lu,Li Ding,Obi L. Griffith,Christopher A. Miller,Dave Larson,Robert S. Fulton,Michelle Harrison,Thomas B. Mooney,Joshua F. McMichael,Jingqin Luo,Yu Tao,Rodrigo Franco Gonçalves,Christopher E. Schlosberg,Jeffrey F. Hiken,Laila Saied,César Sánchez,Therese Giuntoli,Caroline Bumb,Crystal Cooper,R.T. Kitchens,Austin Lin,Chanpheng Phommaly,Sherri R. Davies,Jin Zhang,Megha Shyam Kavuri,Donna McEachern,Yiyu Dong,Cynthia X. Ma,Timothy J. Pluard,Michael Naughton,Ron Bose,Rama Suresh,Reida G. McDowell,Loren S. Michel,Rebecca Aft,William E. Gillanders,Katherine DeSchryver,Richard K. Wilson,Shaomeng Wang,Gordon B. Mills,Ana M. Gonzalez-Angulo,John R. Edwards,Christopher G. Maher,Charles M. Perou,Elaine R. Mardis,Matthew J. Ellis +54 more
TL;DR: Deep sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines.